1177:HKEXSino Biopharmaceutical Limited Analysis

Sino Biopharmaceutical is trading at HK$5.03, just above its 20‑day SMA of 5.10 but well below the 200‑day SMA of 6.08, indicating a medium‑term downtrend. The RSI sits near the midpoint at 50, while the MACD histogram is negative and the signal line is bearish, suggesting short‑term momentum weakness. Volume is decreasing and price is hovering near the identified support of HK$4.70, with resistance around HK$5.47, making the next few sessions price‑sensitive.
Fundamentally, the company delivers robust 9.8% revenue growth, an 82% gross margin and a 12.5% ROE, supported by HK$22.96 bn of cash and a manageable beta of 0.55. Despite a forward PE of 16.7, the current P/E of 33.5 exceeds the industry average, yet the DCF fair value of HK$7.58 implies a 61% upside and the dividend yield of 2% with a 63% payout appears sustainable. The strong pipeline of oncology and liver‑disease drugs, combined with a “Strong Buy” consensus from 20 analysts, positions the stock as an undervalued, growth‑oriented opportunity in a high‑risk biotech sector.